Intro paragraph
Enhabit (EHAB) just wrapped up FY 2025 with Q4 revenue of US$270.4 million and a basic EPS loss of US$0.76, as the company continued to report negative net income of US$38.7 million for the quarter. Over recent periods, revenue has moved from US$258.2 million in Q4 2024 to US$270.4 million in Q4 2025, while basic EPS shifted from a loss of US$0.92 to a loss of US$0.76. This sets up a results season where investors are watching how consistently the business can translate its top line into more resilient margins.
See our full analysis for Enhabit.With the headline numbers on the table, the next step is to see how this earnings print lines up against the prevailing narratives about Enhabit, and where the story investors follow might need updating.
See what the community is saying about Enhabit
LTM losses shrink to US$4.6 million
- On a trailing twelve month basis, Enhabit reported total revenue of US$1.06b and a net loss of US$4.6 million, versus a loss of US$156.2 million on roughly similar revenue of just over US$1.03b a year earlier.
- What stands out for the bullish narrative is that this smaller trailing loss sits alongside revenue growth of about 5.4% per year and analyst expectations for earnings to turn positive within three years. However, trailing results still show the business is unprofitable and that losses have grown at about 47.3% a year over the past five years.
- Bulls point to forecast earnings growth of around 26.6% a year and a shift from a trailing EPS loss of US$0.09 to an expected EPS of roughly US$0.42 to US$0.63 over time, while the historical data in the last 12 months still records negative net income.
- This mix of modest trailing revenue growth and a much smaller LTM loss heavily supports the bullish case that operations are moving closer to breakeven, but the multi year loss growth rate keeps the risk side of that story very present.
Revenue growth at 5.4% trails wider market
- Trailing data shows Enhabit’s revenue growing at about 5.4% per year to US$1.06b, compared with the 10.2% yearly growth rate cited for the broader US market, so top line expansion is slower than that wider benchmark even as the company works toward profitability.
- Critics highlight in the bearish narrative that this steady but slower growth, combined with reimbursement pressure and dependence on Medicare and Medicare Advantage rates, could cap both revenue and margin progress even if branch level initiatives like visit per episode optimisation continue.
- Bears argue that if revenue keeps expanding in the mid single digits while reimbursement cuts continue and wage costs rise, the company may need ongoing cost measures just to hold margins, and the recent quarterly swing from Q3 2025 profit of US$11.1 million to a Q4 2025 loss of US$38.7 million shows how sensitive results can be.
- At the same time, the LTM revenue trend near US$1.06b compared with around US$1.03b previously challenges the most pessimistic view that growth could stall entirely, suggesting operational execution rather than demand alone is central to the bearish case.
Share price below DCF fair value reference
- With the current share price at US$13.61 and a cited DCF fair value reference of about US$38.91, Enhabit is described in the data as trading at a discount, and its P/S ratio of 0.7x sits below both the 1.0x peer average and the 1.3x US Healthcare industry average.
- Consensus narrative notes that this apparent valuation gap rests on analysts expecting revenue to reach roughly US$1.2b and earnings of about US$22.3 million in the coming years, yet trailing twelve month numbers still show a net loss of US$4.6 million and modest 5.4% revenue growth, so the current fundamentals do not yet match the profit profile implied by that fair value.
- On one hand, a P/S of 0.7x against higher peer and industry averages supports the idea that investors are already pricing in the company’s loss history and slower revenue expansion versus the 10.2% market growth rate.
- On the other hand, the gap between the US$13.61 share price and the US$38.91 DCF fair value reference is only likely to close if the forecast move from a small trailing loss to positive earnings actually shows up in future reported numbers. Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Enhabit on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
If this mix of optimism and caution has you on the fence, move quickly to look through the data yourself and decide what really matters for you. To see what the market is finding encouraging right now, take a look at 3 key rewards.
See What Else Is Out There
Enhabit is still working through weak profitability, slower 5.4% revenue growth than the wider US market, and sensitivity to reimbursement changes that can quickly swing results.
If you want ideas with stronger growth and earnings momentum already on show, take a few minutes to scan our 47 high quality undervalued stocks that pair quality fundamentals with attractive prices.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com